间充质 干细胞治疗,新冠肺炎
抽象的
“新冠肺炎” 生活在二十一世纪上半叶的每个人肯定都不会忘记这个词. 新冠肺炎, 作为一种流行病, 促使来自不同生物医学领域的许多研究人员寻找解决方案或治疗方法来应对这一流行病. 然而, no standard treatment for this disease has been discovered to date. Probably, preventing the severe acute respiratory infection form of COVID-19 as the most dangerous phase of this disease can be helpful for the treatment and reduction of the death rate. In this regard, mesenchymal stem cells (间充质干细胞)-based immunomodulation treatment has been proposed as a suitable therapeutic approach and several clinical trials have begun. 最近, MSCs according to their immunomodulatory and regenerative properties attract attention in clinical trials. After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. Given the uncertainties in this area, we reviewed reported clinical trials and hypotheses to provide useful information to researchers and those interested in 干细胞疗法. In this study, we considered this new approach to improve patient’s immunological responses to COVID-19 using MSCs and discussed the aspects of this proposed treatment. 然而, currently, there are no approved MSC-based approaches for the prevention and/or treatment of COVID-19 patients but clinical trials ongoing.
